Figure 3.

Addition of the DNMT3L-Based ETR to the Double tetR:K tetR:D3A Combination Improves Silencing Efficiency

(A) Schematics of the indicated proteins showing the selected effector domains.

(B) Histogram showing the percentage of eGFP negative LV^TetO7/GFP K-562 cells at 21 days post-transfection with plasmids expressing the indicated ETRs (mean ± SEM; n = 3 of three independent transfections for each treatment condition).

(C) Time-course analysis of LV^TetO7/GFP B-lymphoblastoid cells upon transfection with mRNAs encoding for the indicated ETRs. Data show percentage of eGFP-negative cells (mean ± SEM; n = 3 independent transfections for each treatment condition).

(D) Top: schematic of the experimental procedure used to assess activity of the ETRs in primary T lymphocytes and representative dot plot of LV^TetO7/GFP T cells. Bottom: time-course analysis of LV^TetO7/GFP T lymphocytes upon transfection with mRNAs encoding for the indicated ETRs. Data show percentage of eGFP-negative cells as calculated by setting to 100% the percentage of eGFP-positive cells in the untransfected LV^TetO7/GFP condition (mean ± SEM of two independent blood donors each transfected in duplicate). See also Figure S3 and Table S1.